A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 ± niraparib in adults with advanced or metastatic solid tumors.

Authors: Vivek Samnotra, Jimmy Belotte, Veronica Moroz, Luda Shtessel, Patrick Hanafin, Malar Pannirselvam, Aishwarya Bhaskar, Anu Shilpa Krishnatry, Debra Rogan, Haluk Yuzugullu, Minal A. Barve, Philippe Bedard, Quincy S. Chu, Pamela N. Munster, Alexander I. Spira, Ramy R. Saleh, David Sommerhalder, Timothy A. Yap, Brian Andrew Van Tine, Michele Sanicola-Nadel

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3174

Source: Full article

---

Abstract

TPS3174